Interleukin-17 levels correlate with poor prognosis and vascular endothelial growth factor concentration in the serum of patients with non-small cell lung cancer

Biomarkers. 2015;20(4):232-9. doi: 10.3109/1354750X.2015.1068853.

Abstract

Objective: The aim of this study was to explore the clinical role of serum interleukin-17 in patients with non-small-cell lung cancer (NSCLC).

Materials and method: IL-17 expression and microvessel density (MVD) were measured via immunohistochemistry in 58 NSCLC tissues. Serum IL-17 and VEGF levels in NSCLC patients (n = 43) and healthy controls (n = 37) were analyzed via enzyme-linked immunosorbent assay.

Results: Serum IL-17 was elevated and the levels positively correlated with VEGF concentration in NSCLC patients. Multivariate analyses revealed that serum IL-17 levels were an independent prognostic factor in NSCLC.

Conclusion: IL-17 may play a role in NSCLC progression by promoting angiogenesis.

Keywords: Angiogenesis; IL-17; VEGF; non-small cell lung cancer; prognosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antigens, CD34 / analysis
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carcinoma, Non-Small-Cell Lung / blood supply
  • Carcinoma, Non-Small-Cell Lung / blood*
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Immunohistochemistry
  • Interleukin-17 / blood*
  • Kaplan-Meier Estimate
  • Linear Models
  • Lung Neoplasms / blood supply
  • Lung Neoplasms / blood*
  • Lung Neoplasms / diagnosis
  • Lung Neoplasms / drug therapy
  • Male
  • Microvessels / drug effects
  • Microvessels / metabolism
  • Middle Aged
  • Multivariate Analysis
  • Prognosis
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A / blood*

Substances

  • Antigens, CD34
  • IL17A protein, human
  • Interleukin-17
  • Vascular Endothelial Growth Factor A